Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday ...
Hims & Hers (NYSE:HIMS) stock tumbled 20% in post-market trading Monday after the company released its Q4 earnings report and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback